In advanced settings, the AZENT study (NCT02841579) showed promising results for first-line osimertinib for patients with EGFR-mutated NSCLC with a coexisting low allelic fraction of T790M, in which the objective response rate was 77.3% and the median PFS was 23.1 months [54]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.